

## IMMUNOLOGY

August 30, 2022

### Myositis, Systemic Sclerosis and Interstitial Lung Disease Profiles

Date effective: **October 1, 2022**

#### Background Information:

The Shared Health Immunology Laboratory at St Boniface Hospital is pleased to announce the introduction of three new tests to aid in the diagnosis of systemic autoimmune rheumatic diseases (SARDs) and associated interstitial lung disease.

Our laboratory strives to provide efficient, reliable, and high-quality services that contribute to enhanced patient care. By providing this service in-house we can ensure testing is performed on fresher samples resulting in more accurate interpretation and reduce turn-around times to assist in earlier diagnosis and treatment.

#### Clinical Practice Change:

Previously referred to Mitogen Dx in Alberta, testing will now be performed by the Immunology Lab at St. Boniface Hospital using the same methodology - Line Immunoassay (LIA). This test provides qualitative in vitro determination of human antibodies of immunoglobulin classes IgG in patient serum. ANA testing should be performed in the initial evaluation of SARDs. Antibodies in SARDs can target the nucleus as well as any intracellular components of the cell, most notably the cytoplasm. The International Consensus on ANA Patterns (<https://anapatterns.org/index.php>) has comprehensive information on patterns, targets, and clinical associations.

<b>Myositis Profile</b>
Mi-2 $\alpha$ , Mi-2 $\beta$ , TIF1 $\gamma$ , MDA5, NXP2, SAE1, Ku, PM-Scl100, PM-Scl75, Jo-1, SRP, PL-7, PL-12, EJ, OJ, and Ro-52
<b>Systemic Sclerosis Profile</b>
Scl-70, CENP A, CENP B, RP11 and RP155 (RNA Polymerase III subunits), fibrillarin, NOR90, Th/To, PM-Scl100, PM-Scl75, Ku, PDGFR (platelet derived growth factor) and Ro-52
<b>Interstitial Lung Disease Profile</b>
Mi-2 $\alpha$ , Mi-2 $\beta$ , TIF1 $\gamma$ , MDA5, NXP2, SAE1, Ku, PM-Scl100, PM-Scl75, Jo-1, SRP, PL-7, PL-12, EJ, OJ, Ro-52, Scl-70, CENP A, CENP B, RP11 and RP155 (RNA Polymerase III subunits), fibrillarin, NOR90, Th/To, and PDGFR (platelet derived growth factor).

**\*\*\*Testing will be restricted to Specialists or via prior approval\*\*\***

#### References/Resources:

Test: [Laboratory Information Manual - Myositis Profile](#)  
[Laboratory Information Manual - Systemic Sclerosis Profile](#)  
[Laboratory Information Manual - Interstitial Lung Disease Profile](#)

Delphic Code: MYOP (Myositis Profile); SSP (Systemic Sclerosis Profile); ILDP (Interstitial Lung Disease Profile)

Sample: Serum 1.0 ml

Normal Range: Negative

Note: Positive results will report with Weak, Moderate or Strong Intensity

Availability: Weekdays (5-7day TAT)

Requisition: Immunology Autoimmune Laboratory Requisition [R250-10-85 V02 – Effective Oct 1, 2022]

**Patient Impact:**

- TAT reduced from 14+ days

**System Improvements:**

- Improved sustainability
- Decreased operating costs

**Contact Information:**

- Dr. Ping Sun, Hematopathologist, Medical Director Hematology & Immunology, Shared Health Manitoba, (phone: 204-787-4682) [psun@sharedhealthmb.ca](mailto:psun@sharedhealthmb.ca)
- Jason Warren, Immunology Technical Manager, Shared Health Manitoba, (phone: 204-787-3407) [jwarren3@sharedhealthmb.ca](mailto:jwarren3@sharedhealthmb.ca)